Total Payments
$6,891
2024 Payments
$1,266
Companies
29
Transactions
361
Medicare Patients
749
Medicare Billing
$58,866
Payment Breakdown by Category
Food & Beverage$6,871 (99.7%)
Education$20.00 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,871 | 360 | 99.7% |
| Education | $20.00 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $745.37 | 38 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $675.90 | 36 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $610.26 | 40 | $0 (2024) |
| CSL Behring | $576.99 | 29 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $503.84 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $454.66 | 28 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $354.68 | 11 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $338.81 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $316.08 | 15 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $313.95 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,266 | 52 | CSL Behring ($198.45) |
| 2023 | $1,511 | 72 | Alexion Pharmaceuticals, Inc. ($177.59) |
| 2022 | $787.11 | 38 | E.R. Squibb & Sons, L.L.C. ($125.39) |
| 2021 | $21.03 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21.03) |
| 2020 | $329.62 | 19 | Janssen Pharmaceuticals, Inc ($77.67) |
| 2019 | $1,139 | 68 | Janssen Pharmaceuticals, Inc ($185.99) |
| 2018 | $1,054 | 65 | E.R. Squibb & Sons, L.L.C. ($135.21) |
| 2017 | $782.43 | 46 | PFIZER INC. ($216.03) |
All Payment Transactions
361 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.41 | General |
| 12/19/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $29.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.64 | General |
| 11/14/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $25.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $35.85 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/05/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/31/2024 | CSL Behring | Kcentra (Biological) | Food and Beverage | In-kind items and services | $29.07 | General |
| Category: Trauma (Emergency, Injury, Surgery) | ||||||
| 10/24/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $31.17 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.74 | General |
| 10/08/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/30/2024 | CSL Behring | Kcentra (Biological) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Trauma (Emergency, Injury, Surgery) | ||||||
| 09/27/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.71 | General |
| 09/16/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/10/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.56 | General |
| 08/29/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/28/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/22/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $30.77 | General |
| Category: HEMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 99 | 132 | $24,152 | $7,922 |
| 2022 | 5 | 116 | 159 | $19,668 | $8,891 |
| 2021 | 5 | 220 | 326 | $37,320 | $17,382 |
| 2020 | 5 | 314 | 441 | $51,915 | $24,670 |
Total Patients
749
Total Services
1,058
Medicare Billing
$58,866
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 47 | $8,751 | $2,801 | 32.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 25 | $6,692 | $2,331 | 34.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 33 | $3,323 | $1,284 | 38.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 12 | $2,859 | $920.16 | 32.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 15 | $2,527 | $585.35 | 23.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 36 | 60 | $6,971 | $3,354 | 48.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 36 | $5,975 | $2,787 | 46.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 24 | 37 | $3,145 | $1,084 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $1,938 | $865.56 | 44.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 15 | $1,638 | $800.61 | 48.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 99 | 166 | $19,090 | $9,245 | 48.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 41 | $6,560 | $3,228 | 49.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 53 | 77 | $6,545 | $2,339 | 35.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 24 | 31 | $3,255 | $1,686 | 51.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 11 | 11 | $1,870 | $884.95 | 47.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 172 | 276 | $31,740 | $15,772 | 49.7% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 56 | 56 | $8,680 | $3,910 | 45.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 22 | $3,520 | $1,893 | 53.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 47 | 58 | $4,930 | $1,866 | 37.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 29 | $3,045 | $1,229 | 40.3% |
About Dr. Amy Gates, MD
Dr. Amy Gates, MD is a Hospitalist healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356444707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Gates, MD has received a total of $6,891 in payments from pharmaceutical and medical device companies, with $1,266 received in 2024. These payments were reported across 361 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($6,871).
As a Medicare-enrolled provider, Gates has provided services to 749 Medicare beneficiaries, totaling 1,058 services with total Medicare billing of $58,866. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Internal Medicine
- Location Dallas, TX
- Active Since 09/07/2006
- Last Updated 03/06/2023
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1356444707
Products in Payments
- ELIQUIS (Drug) $970.48
- XARELTO (Drug) $675.90
- Kcentra (Biological) $576.99
- REBYOTA (Biological) $354.68
- XIFAXAN (Drug) $338.81
- JARDIANCE (Drug) $331.61
- LOKELMA (Drug) $316.08
- Veltassa (Drug) $314.84
- DIFICID (Drug) $277.53
- ULTOMIRIS (Biological) $275.24
- Fetroja (Drug) $249.42
- ENTRESTO (Drug) $248.10
- TEFLARO (Drug) $187.52
- CHANTIX (Drug) $179.96
- CRESEMBA (Drug) $178.66
- ZERBAXA (Drug) $177.13
- PRADAXA (Drug) $125.78
- VYNDAQEL (Drug) $84.99
- Caldolor (Drug) $82.86
- Arikayce (Drug) $78.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in Dallas
Dr. Ali Bagheri, Md, MD
Hospitalist — Payments: $11,446
Hospitalist $11,446
Janae' Richard
Hospitalist — Payments: $9,928
Hospitalist $9,928
Dr. Anita Khetan, M.d, M.D
Hospitalist — Payments: $9,685
Hospitalist $9,685
Rainer Khetan, M.d, M.D
Hospitalist — Payments: $8,606
Hospitalist $8,606
Dr. Radha Yalamanchili, Md, MD
Hospitalist — Payments: $6,937
Hospitalist $6,937
Akua Fordjour, Md, Phd, MD, PHD
Hospitalist — Payments: $6,705
Hospitalist $6,705